A biologics contract manufacturing organization and biotechnology company, iBio, announced in a March 26, 2020 press release that immunization studies for its SARS-CoV-2 Virus-Like Particle (VLP) program, called IBIO-200, are proceeding at Texas A&M University System (TAMUS) laboratories. The work is being performed as part of a master joint development agreement established between iBio and TAMUS in 2016.
